Erika Carmel-Tech Ltd (ERKA) Fair Value & Analysis
Healthcare · Il · Market cap 21.1M ILA
Fair value as of: Jul 19, 2026
From 9 valuation models · updated 22 days ago
Fair value updated Jul 19, 2026, revised from 0.3900 ILA to 0.4500 ILA (+15.4%) since Jul 16, 2026. Share price −11.8% over the past month.
A solid business, but screening 10% overvalued on our models.
What matters now
- Our model range runs from 0.3300 ILA (bear) to 0.5800 ILA (bull), base 0.4500 ILA. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 63/100 (solid quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.
How to read this chart
60‑month range 0.2803 ILA – 19.69 ILA · fair‑value band 0.3300 ILA – 0.5800 ILA · the 0.5010 ILA price screens above the 0.4500 ILA fair value. Dashed = 300-day average. As of Jul 19, 2026.
Analysis
Erika Carmel-Tech Ltd (ERKA) currently trades at 0.5010 ILA, while our model-based Fair Value estimate is 0.4500 ILA, implying the stock looks roughly 10.2% overvalued today. The Quality Score stands at 63/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Erika Carmel-Tech Ltd generated revenue of 37.3M ILA at a net margin of -15.7%. Revenue declined 12.2% year over year. It earns a return on equity of -47.2%. The balance sheet holds a net cash position of 1.3M ILA. Fundamentals as of Jul 19, 2026
Our scenario range runs from 0.3300 ILA (bear case) to 0.5800 ILA (bull case); at 0.5010 ILA, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -10%, ERKA screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 9 models by family
Widest divergence: Dividend Discount (0.8800 ILA) versus Asset-Based (0.1600 ILA). Highest evidence: Growth DCF (80).
Notify me when ERKA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 28
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Erika Carmel-Tech Ltd develops, manufactures, markets, distributes, and sells the B-Cure laser products in Israel and internationally.
Full company description
Erika Carmel-Tech Ltd develops, manufactures, markets, distributes, and sells the B-Cure laser products in Israel and internationally. It provides B-Cure Laser Classic, a non-invasive and safe medical device for the treatment of chronic and acute pain for home use; and B-Cure Laser Pro, a clinically proven, non-invasive and safe medical device for treatment of both acute and chronic conditions. The company treats achilles tendon inflammation, burns, carpal tunnel syndrome, finger joint pain, fibromyalgia, hip pain, post-dental treatment, lower back pain, neck pain, shoulder pain, knee pain, tennis elbow, toe joint pain, temporomandibular joint disorders, upper back pain, and wounds. The company was formerly known as Erika B-Cure Laser Ltd and changed its name to Erika Carmel-Tech Ltd in October 2025. Erika Carmel-Tech Ltd was incorporated in 2007 and is headquartered in Haifa, Israel.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Erika Carmel-Tech Ltd reported revenue of 37.3M ILA in FY2025 versus 96.9M ILA in FY2021, a compound −21.2%/yr. Reported net income was −5.9M ILA in FY2025.
ERKA screens 10% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Erika Carmel-Tech Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Erika Carmel-Tech Ltd (ERKA) overvalued or undervalued?
What is the fair value of ERKA?
What is the quality score of ERKA?
What is the revenue of Erika Carmel-Tech Ltd (ERKA)?
What is the net profit margin of ERKA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Erika Carmel-Tech Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.